Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor

Evaluating teclistamab for patients with recurrent or unresponsive multiple myeloma

Evaluating teclistamab for patients with recurrent or unresponsive multiple myeloma

Posted by on Oct 9, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of teclistamab (JNJ-64007957) for patients with recurrent or unresponsive multiple myeloma (MM). This study concluded that this treatment was safe and showed promising effectiveness for these patients. Some background Multiple myeloma is a type of cancer of the bone marrow that can...

Read More

Effects of combined treatment with venetoclax, daratumumab and dexamethasone with or without bortezomib in patients with relapsed or refractory multiple myeloma.

Effects of combined treatment with venetoclax, daratumumab and dexamethasone with or without bortezomib in patients with relapsed or refractory multiple myeloma.

Posted by on Sep 19, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of a venetoclax (Venclexta), daratumumab (Darzalex), and dexamethasone (Decadron combination with or without bortezomib (Velcade) in patients with relapsed or refractory (RR) multiple myeloma (MM). The authors concluded that these treatment combinations produced high...

Read More

Evaluating the long-term effectiveness and safety of tandem CAR T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma.

Evaluating the long-term effectiveness and safety of tandem CAR T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma.

Posted by on Aug 22, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the long-term safety and effectiveness of tandem chimeric antigen receptor (tCAR) T-cell therapy for patients with relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL). The data showed that tCAR T-cell therapy resulted in long-term remission rates with manageable side effects for these patients. Some...

Read More

Is surgery of metastases effective after failure of modern whole-body treatments in patients with advanced melanoma?

Is surgery of metastases effective after failure of modern whole-body treatments in patients with advanced melanoma?

Posted by on Aug 22, 2021 in Melanoma | 0 comments

In a nutshell This study looked at the use of surgery for spread disease (metastases) in patients with advanced melanoma when other whole-body treatments had failed. It found that surgical removal of metastases improved the outcomes of these patients. Some background Advanced melanoma can spread to many places in the body. It is usually...

Read More

How useful is a carfilzomib, bendamustine, and dexamethasone treatment combination for hard-to-treat multiple myeloma?

How useful is a carfilzomib, bendamustine, and dexamethasone treatment combination for hard-to-treat multiple myeloma?

Posted by on Aug 15, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study reported the safety and effectiveness of a combination of carfilzomib (Kyprolis), bendamustine (Treanda), and dexamethasone (Decadron) for patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that a combination of carfilzomib, bendamustine, and dexamethasone (CBd) showed promising...

Read More

Can a combination of brentuximab vedotin and salvage chemotherapy treat classical Hodgkin’s lymphoma not responding to standard treatment?

Can a combination of brentuximab vedotin and salvage chemotherapy treat classical Hodgkin’s lymphoma not responding to standard treatment?

Posted by on Aug 15, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at the combination of brentuximab vedotin (BV; Adcetris) and ICE salvage chemotherapy with ifosfamide (Ifex), carboplatin (Paraplatin), and etoposide (Etopophos) for the treatment of relapsing or refractory Hodgkin lymphoma (HL). This study showed that BV-ICE was a good salvage treatment option for...

Read More

Searching for patients with unresponsive B-cell lymphoma to trial an experimental treatment.

Searching for patients with unresponsive B-cell lymphoma to trial an experimental treatment.

Posted by on Aug 15, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including non-Hodgkin lymphoma (NHL), that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment. This trial...

Read More

Evaluating dual-target CAR T-cell therapy for patients with unresponsive B-cell NHL

Evaluating dual-target CAR T-cell therapy for patients with unresponsive B-cell NHL

Posted by on Aug 8, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of dual chimeric antigen receptor (CAR) T-cell therapy for patients with recurrent or hard-to-treat B-cell non-Hodgkin lymphoma (NHL). This study found that this treatment was safe and effective for these patients. Some background B-cell non-Hodgkin’s lymphoma (NHL) is one of...

Read More

Comparing the safety and effectiveness of regorafenib versus TAS-102 for the treatment of patients with unresponsive metastatic colorectal cancer.

Comparing the safety and effectiveness of regorafenib versus TAS-102 for the treatment of patients with unresponsive metastatic colorectal cancer.

Posted by on Aug 7, 2021 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of regorafenib (Stivarga) versus TAS-102 (Lonsurf; trifluridine-tipiracil) for the treatment of patients with unresponsive metastatic colorectal cancer (mCRC). The data showed that both treatments were safe and lead to similar survival outcomes for primary and secondary treatment of...

Read More

Evaluating long-term outcomes of autologous SCT for patients with recurrent multiple myeloma

Evaluating long-term outcomes of autologous SCT for patients with recurrent multiple myeloma

Posted by on Aug 7, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the outcomes of autologous stem cell transplantation (ASCT) for patients with recurrent multiple myeloma (MM). This study found that long-term outcomes for these patients were promising, especially for patients who had the transplant right away after a first relapse. Some background Multiple myeloma (MM) is a type of...

Read More

Is Ixazomib, thalidomide and dexamethasone effective in treating relapsed and/or refractory multiple myeloma?

Is Ixazomib, thalidomide and dexamethasone effective in treating relapsed and/or refractory multiple myeloma?

Posted by on Jul 11, 2021 in Multiple Myeloma | 0 comments

In a nutshell This article looked at the effectiveness and safety of continuous ixazomib (Ninlaro), thalidomide (Thalomid), and dexamethasone (Decadron) (ITd) in the treatment of relapsed and/or refractory (RR) multiple myeloma (MM). The authors found that this regimen was well tolerated and showed promising effectiveness in the treatment of...

Read More